GlobeNewswire Inc.··NaArcutis Reports 65% YoY Growth in ZORYVE Revenue Despite Seasonal Decline
Arcutis reports Q1 2026 ZORYVE revenue of $105.4 million, up 65% year-over-year, with expanded pediatric development and reaffirmed full-year guidance of $480-495 million.
ARQTFDA approvalclinical trial